Voxelotor Brain Oxygenation and Neurocognitive Study

Summary

This is an open label, single arm multicenter trial to evaluate the effect of voxelotor treatment on cerebral blood flow (CBF) and neurocognitive function in adolescent and young adult participants (12-30 years of age) with sickle cell disease (SCD).

Timeline

Start

2023-08-09

Primary completion

2023-08-23

Completion

2023-08-23

Drugs

Indications